Viska Bio
Viska Bio is developing a proprietary antibody-enzyme fusion protein to induce anti-tumor immune responses through targeted oxidative damage. Our approach delivers superoxide directly into the tumor microenvironment, inducing immunogenic cell death. The lead program targets glioblastoma (GBM), an aggressive brain cancer with poor immune infiltration and limited treatments. Our plug-and-play platform enables tumor-specific targeting via nanobody exchange, so while GBM is our focus, we are also exploring additional indications including colorectal cancer and multiple myeloma.
